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Abstract 
 
Background: The National Cancer Institute Moonshot℠ research initiative calls for 
improvements in the analysis and reporting of treatment toxicity to advise key stakeholders on 
treatment tolerability and inform regulatory and clinical decision-making. This study illustrates 
alternative approaches to toxicity evaluation using the National Surgical Adjuvant Breast and 
Bowel Project (NSABP-R04) clinical trial as an example.   
 
Methods: NSABP-R04 was a neoadjuvant chemo-radiation trial in stage II-III rectal cancer 
patients. A 2x2 factorial design was used to evaluate whether the addition of oxaliplatin (Oxa) to 
5-fluorouracil (5FU) or capecitabine (Cape) with radiation therapy improved local-regional 
tumor control. The toxicity index (TI), which accounts for the frequency and severity of 
toxicities, was compared across treatments using multivariable probabilistic index models 
(PIMs), where Pr A < B indicates the probability that higher values of TI were observed for A 
when compared to B. Baseline age, gender, performance status (PS), body mass index (BMI), 
surgery type and stage were evaluated as independent risk factors. 
 
Results: A total of 4,560 toxicities from 1,558 patients were analyzed. Results from adjusted 
PIMs indicate that oxaliplatin-containing regimens had statistically significant (p<0.001) 
probability for higher TI compared to regimens without oxaliplatin: Pr 5FU < 5FU + Oxa = 
0.619 (95% CI 0.560-0.674); Pr 5FU< Cape + Oxa = 0.627 (95% CI 0.568-0.682); Pr Cape < 
5FU + Oxa =0.587 (95% 0.527-0.644); and Pr Cape < Cape+ Oxa = 0.596 (95% 0.536-
0.653).When compared to other existing toxicity analysis methods, TI provided greater power to 
detect differences between treatments. 
 
Conclusions: This paper uses standard data collected in a cancer clinical trial to introduce 
descriptive and analytic methods that account for the additional burden of multiple toxicities. 
These methods may provide a more accurate description of a patient’s treatment experience that 
could lead to individualized dosing for better toxicity control. Future research will evaluate the 
generalizability of these findings in trials with similar drugs. 
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For more than 60 years, cancer clinical trials have used an observer-rated toxicity grading 
system: Common Terminology Criteria for Adverse Events (CTCAE), which assesses the 
severity of various organ system toxicities associated with treatment.1 CTCAE data collection in 
a trial provides detailed longitudinal information on the severity and types of toxicity. However, 
standard methods for summarizing CTCAE toxicities do not capture the complete toxicity 
experience over the course of treatment. For instance, maximum grade analysis involves the 
aggregation of toxicities by highest grade experienced over time and does not account for the 
cumulative burden that multiple toxicities may introduce, or the persistence and chronicity of 
some lower-grade toxicities.2-6   
Toxicity reports are further limited by ignoring baseline risk factors that may contribute to 
treatment burden. Although information on demographic and clinical characteristics is collected 
for most clinical trials, it is often presented separately and seldom evaluated within the context of 
toxicity. Understanding which factors predict greater toxicity is critical to determining optimal 
treatment approaches and identifying those at higher risk for toxicity. For instance, host factors 
such as baseline performance status, older age, and gender, or disease-specific factors such 
clinical stage or surgery type received, are known predictors of survival and treatment outcomes, 
and should be considered when evaluating toxicity.7,8,9,10 In recognition of deficiencies in toxicity 
reporting, the National Cancer Institute (NCI) launched a Cancer Moonshot℠ funding 
opportunity to accelerate research on improved approaches to evaluating the tolerability of 
cancer treatments.  
This paper examines new strategies for understanding treatment toxicity applied to existing 
data from a large randomized clinical trial, the National Surgical Adjuvant Breast and Bowel 
Project (NSABP-R04).11,12 Using new statistical approaches and graphical displays to summarize 
the toxicity data, we demonstrate how one can optimize the use of available information and 
provide a more complete and accurate account of which patients are at greatest risk for toxicity at 
the completion of a trial. 
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Methods   
 
 
Methods for analyzing toxicity 
We applied three different methods for analyzing toxicity: the toxicity index (TI)13, the 
maximum grade and average toxicity. The TI was developed as a summary measure to better 
discriminate patients based on their overall toxicity experiences, accounting for all observed 
toxicity grades rather than just the most severe one.13 A subject’s TI score is defined as a 
function of the ordered toxicity grades, where the toxicity grades are represented in descending 
order by the sequence. The TI is computed according to the following algorithm:14   
 
The TI has the following properties: Any score 3 corresponds to the usual definition of dose 
limiting toxicity (DLT), and the maximum toxicity grade is the integer part of the final score. For 
example, a TI=3.0 indicates a single grade 3 toxicity, whereas a score of 3.5 indicates at least one 
grade 3 toxicity plus additional toxicity; all toxicity grades are represented in the score, though 
lower grades contribute less to the final score; the score is a number between 0 and 5.83 (See 
Supplementary Material for explanation of upper limit); Multiple toxicities of the same grade 
yield a TI score slightly less than that generated by a single toxicity of the next higher grade; and 
when several patients are compared with relation to their toxicity profile, the TI preserves their 
ranking.  
The second approach, maximum grade analysis, yields an incidence rate that is summarized 
by the most severe grade observed across all events, independent of time of occurrence.2-4 For 
example, a subject experiencing multiple high-grade toxicities across organ systems, is noted as 
having only experienced a single high-grade toxicity overall. We also compute the average 
toxicity, which is the summary statistic used in the Toxicity-Over-Time (Tox-T) approach,13,15 
which requires analysis across multiple treatment cycles.    
 
Data Source 
Data from the NSABP-R04 rectal cancer clinical trial were used as a case example for this 
research.12  NSABP-R04 was a phase 3 trial conducted between July 2004 and August 2013 
(NCT00058474). Eligible patients were diagnosed with surgically resectable stage II or III rectal 
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adenocarcinoma. The trial was approved by the local Institutional Review Boards and all patients 
provided written consent, as detailed in the main trial report; however, these secondary analyses 
were deemed exempt by our institutional IRB.12 When the trial first opened, patients were 
randomized to two treatment groups: Infusional 5-fluorouracil (5FU) with pelvic radiation 
therapy (RT) compared to oral capecitabine (CAPE) with pelvic RT. In 2005, the protocol was 
amended to add an oxaliplatin (Oxa) option to 5FU and CAPE, resulting in a 2x2 factorial design 
with four treatment groups: 5FU + RT; 5FU + Oxa + RT; CAPE + RT; CAPE + Oxa+RT. The 
doses for 5FU and CAPE for the 4-arm amended trial were reduced from seven to five days a 
week post-amendment to allow for the addition of Oxa12 (Figure 1). Surgery was performed 
within 6 to 8 weeks after RT completion. The primary outcome was local-regional tumor control, 
defined as time to local or regional recurrence or surgery if an R0 resection was not achieved. 
Oxa did not improve the primary outcome, and there was no statistically significant difference 
between the CAPE and 5FU alone arms.12 As a result, CAPE with RT has now become the 
standard of care in subsequent trials.  
Baseline assessments included demographics, medical history, height, weight, vitals, physical 
exam, quality-of-life, imaging, and bloodwork. Laboratory tests (e.g., CBC/Differential, 
Platelets, Bilirubin, ALP, AST, etc.) were evaluated weekly during treatment and two weeks 
prior to surgery. Toxicity assessment was conducted using CTCAE version 4.0 graded from 0 
(least severe) to 5 (most severe) and grouped by 26 system organ classes. AEs were collected at a 
single time point after chemoradiation treatment within two weeks of surgery. Over 50 AEs of 
special interest were selected a priori based on clinical expertise concerning the study regimens 
and evaluated systematically during treatment (Supplementary Table 1). Quality of life 
questionnaire data was collected prior to treatment, at the end of chemoradiation prior to surgery, 
and then 12 months after surgery, and has been reported in part elsewhere, 11 and is not included 
here. Patient follow-up for survival and disease progression occurred at every 12 months from 
surgery for the first two years. The trial included 1,608 participants, with complete toxicity data 
available for 1,558 patients (our analysis sample). Additional information about the trial design 
and study population is reported elsewhere.11,12 
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Statistical Analysis 
 
Graphical summaries of the toxicity data included box plots, histograms, and 
combinations of graphical and tabular results. All graphical summaries were produced in the R 
statistical package.  
Probabilistic Index Models (PIMs), a rank-based method that generalizes the Kruskal-
Wallis test, were fit to compute the probability of higher toxicity between groups.16-20 For 
example, considering a score S for groups A and B, a probability Pr(SA < SB) equal to 0.5 
indicates that both groups have similar score S distributions; a probability statistically 
significantly greater than 0.5 (Pr > 0.5) gives evidence that group B has higher score S than 
group A; a probability statistically significantly less than 0.5 (Pr < 0.5) gives evidence that group 
B has a lower score S than group A. The probability that a score S for one group is greater than 
or equal to a score S for another group was estimated with a Wald-type 95% confidence interval. 
P-values were calculated using the Wald statistic, and p-values for multiple comparisons were 
corrected using Holm’s adjustment.21 In addition, we defined body system-specific TI as the TI 
calculated considering only toxicities in a given specific body system. Separate PIMs were then 
fit for each body system that had at least 10 non-zero TI values. All PIMs incorporated 
covariables of interest, including gender, age, Karnofsky Performance Status (KPS), clinical 
stage, and intended surgery (sphincter or non-sphincter preserving) at entry. Tests for 
interactions between gender and treatment were assessed, where an interaction effect was present 
if the interaction term in the PIMs was statistically significant (p<0.05). If the interaction term 
was not statistically significant, the term was removed from the model. To compare the 
performance of different analytic approaches, the power to detect treatment differences was 
estimated for sample sizes of 50, 75, 100, …, 300 patients for each method (TI, Maximum-
Grade, Average Toxicity) based on 2000 resamples. Calculations were performed using the R-
package pim,22 and all hypotheses were two-tailed and tested at the 5% statistical significance 
level. 
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Results 
Patient characteristics 
 
The analytic sample consisted of 1,558 eligible patients. There were 141 subjects analyzed in 
each treatment group from the 2-arm trial (pre-amendment): (Group 1) 5FU + RT (2-Arm) and 
(Group 2) CAPE + RT (2-Arm). In the 4-arm 2x2 factorial trial, 316 subjects were randomized to 
5FU + RT (Group 3), 321 to 5FU + Oxa + RT (Group 4), 318 to CAPE + RT (Group 5), and 321 
to CAPE + Oxa + RT (Group 6) (Figure 1). Demographic characteristics including age, gender, 
clinical stage, and surgical treatment intent were well-balanced across groups as previously 
reported.12 
 
 
Treatment toxicity 
 
In this study, our only toxicity assessment timepoint was at the end of chemo-radiation 
therapy and before surgery. Among 1,558 eligible patients from all treatment groups (2-Arm and 
4-Arm) there were a total of 4,560 toxicities, of which 3,720 toxicities occurred in the subgroup 
of 1,276 patients in the 4-Arm trial (post-amendment). Figure 2 shows the relative proportion of 
toxicities for each toxicity severity (Y-axis) by the number of toxicities that occurred per patient 
(X-axis). From this figure, it can be observed that the number ranged from 0-24 toxicities per 
patient, with the most frequent and severe toxicities occurring in patients treated with Oxa 
combined with 5FU or CAPE (Figure 2).   
TI was calculated to provide a quantitative measure of the cumulative burden of treatment 
toxicity. A summary of the mean, median and interquartile ranges for TI is provided in Table 1. 
TI was lowest in the 5FU 4-Arm Trial (Median = 2.33) and highest in the CAPE + Oxa and 5FU 
+ Oxa arms (Median= 2.98) (Table 1). The mode of the distribution of toxicities per patient was 
0 for 5FU, 3 for CAPE, and 4 for both 5FU+Oxa and CAPE+Oxa (Supplementary Figure 1). 
Patients with 1 or 2 toxicities tended to have a median TI < 3, while patients with more than 4 
toxicities displayed a median TI > 3, which is typically classified as dose-limiting toxicity 
(DLT). Figure 3 shows that TI increased with the increasing number of toxicities per patient in 
each treatment group, thus demonstrating that the severity of toxicities also increases with the 
number of toxicities occurring per patient. 
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Probabilistic Index Models 
 
In univariable analysis (Supplementary Table 2)., older age, female gender, planned non-
sphincter saving surgery, poor KPS (50-60), and BMI <18.5 were statistically significantly 
associated with increased probability (Pr > 0.5) for higher TI. Treatment with CAPE + Oxa and 
5FU+ Oxa also had increased probability of higher TI than either 5FU or CAPE alone (4-arm) 
(Supplementary Table 2). Additionally, the higher dose of 5FU (2-arm) was associated with 
greater toxicity as compared to the 4-arm regimen. There were no statistical differences observed 
between 5FU and CAPE (4-arm) or 5FU + Oxa and CAPE + Oxa. 
Multivariable PIMs for the 2-Arm and 4-Arm trials are shown in Tables 2 and 3, 
respectively. The adjusted probability that the 5FU 2-arm had a higher TI than 4-arm (Pr= 0.57, 
95% CI 0.51, 0.63, p=0.02) and the probability the CAPE 2-arm had a higher TI than the 4-arm 
(Pr=0.56, 95% CI 0.50, 0.62, p=0.05) were greater than 0.5, showing that 2-arm single 
treatments were more toxic than 4-arm single treatments, but only the comparison between the 
5FU 2-arm and 4-arm trials was statistically significant (Table 2). 
Oxaliplatin-containing regimens also had statistically significant probability (Pr>0.5) for 
higher TI compared to regimens without oxaliplatin in the 4-arm trials: Pr 5FU < 5FU + Oxa= 
0.619 (95% CI 0.560-0.674); Pr 5FU< Cape + Oxa = 0.627 (95% CI 0.568-0.682); Pr Cape < 
5FU + Oxa =0.587 (95% 0.527-0.644); and Pr Cape < Cape+ Oxa = 0.596 (95% 0.536-0.653) 
(Table 3). Baseline characteristics independently associated with increased probability of higher 
toxicity included female gender, poor KPS, low BMI (<18.5) and planned non-sphincter 
preserving surgery (Table 3). No statistically significant interaction between gender and 
treatment was observed (p=0.97). We did observe that females had statistically significant higher 
toxicity than males using body system-specific TI for the following body systems: Blood, 
Gastrointestinal, General, Investigations, Metabolism, and Reproductive (Table 4).  
 
Comparison with existing toxicity methods 
 
Results from adjusted PIMs for each analysis method (TI, Max-grade, Average Toxicity) 
are graphically represented in Figure 4. The corresponding numerical estimates and 95% 
confidence intervals are available in Supplementary Table 3. Overall, point estimates for the 
probability of higher score were of greater or equal value when TI was used as compared to 
maximum grade for all comparisons, except CAPE (2 Arm) < CAPE (4 Arm).   
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  While point estimates and measures of precision were comparable for TI and maximum 
grade, TI had greater power to detect differences between treatments (Figure 5). Thus, the use of 
TI results in a smaller number of patients needed to detect differences in treatments. For 
example, a sample size of 95 would be required to detect a difference between 5FU and 5FU + 
Oxa using TI. The same comparison would require a sample of 117 patients for the maximum 
grade method or 137 for the Average Toxicity method, resulting in a 19% and 31% difference in 
required sample sizes, respectively (Figure 5, Supplementary Table 3). 
 
Discussion 
 
Current approaches for analyzing and reporting clinical trial toxicity data are limited and 
do not capture the complete picture of a patient’s treatment experience. Most analyses have 
defaulted to the maximum grade approach, which collapses toxicities across all grades, organ 
systems, and ignores the extensive toxicity data and baseline risk factors that are available. In 
this paper, we demonstrate the feasibility of a more comprehensive approach to the presentation 
and analysis of toxicity data using the NSABP R04 clinical trial as a case example.  
Findings from this analysis revealed important differences in toxicity across treatment 
arms. By supplementing visual displays with the computation of TI scores, we were able to 
demonstrate the positive relationship between the frequency and severity of toxicities.  
The TI also allowed for treatment comparisons, where the probability of a treatment 
having higher toxicity can be adjusted for baseline factors using PIMs. Applying this method to 
NSABP R04 toxicity data resulted in statistically significant differences in toxicity between 
treatment arms that combined 5FU or CAPE with Oxa and RT. The TI was also sensitive to 
differences in doses of 5FU where toxicity in the 2-Arm trial, at a higher dose (7 days), was 
statistically greater than the lower dose (5 days) in the 4-arm trials. While the primary NSABP 
R04 trial publication described differences in the percentage of grade 3-4 toxicities in the 2-Arm 
and 4-Arm trials, it did not reach statistical significance.12 Further, there was no information 
about the frequency or occurrence of less-severe toxicities, using the standard maximum grade 
approach to present safety results.  
Existing trial reports also failed to describe the additional risk that baseline factors may 
contribute to our understanding of the overall toxicity burden and tolerability of treatment 
regimens on subgroups of patients within the setting of a randomized trial. Using adjusted PIMs, 
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we compared TI across treatments and patient characteristics. We found that older age, female 
gender, worse KPS, and clinician intent for non-sphincter-preserving surgery were statistically 
associated with higher probability of subsequent toxicity. While the prognostic values of some of 
these host factors for survival (e.g., age, KPS) are established in the literature, we know of few 
reports that describe the impact of baseline host factors on treatment toxicity.23,24,25,26 When 
reported, these analyses usually occur in secondary analyses long after the primary trial result, 
and thus may not be promptly reported to the clinicians adopting a treatment regimen. Reporting 
on baseline characteristics that are risk factors for greater toxicity can better prepare clinicians 
who apply trial results to the treatment of patients in their clinical practice.   
 Our analysis also uncovered interesting differences in toxicity that are independently 
associated with gender. Overall, females had statistically significantly higher toxicity across 
treatments and body systems than males. It is unclear whether these differences are a result of 
differences in clinician reports by gender, or if females are at greater risk for toxicity. Earlier 
studies, more than two decades ago, reported gender-related differences in 5FU toxicity related 
to hematological toxicity and mucositis, but the sample size and quality of these studies were 
limited.23,27-29 Thus, this analysis greatly expands on these past observations, showing multi-
system toxicities. We plan to evaluate our gender-related findings in another adjuvant colon 
cancer trial comparing 5FU with or without Oxa. We have also begun to explore whether there 
are gender differences in the PRO data that were collected in the R04 trial.11 The National 
Institutes of Health now requires all research applications to discuss gender as a biological 
variable and there are increasing reports of gender differences in the newer immunotherapy 
treatment trials, where there are known differences between men and women with regard to the 
immune system as well as other factors.30  In retrospect, we may have missed an opportunity to 
identify an important variable that is closely related to treatment toxicity and tolerability for 
some regimens, and future evaluations of treatment toxicity should consider gender-specific 
evaluations of toxicity.    
There are several strengths associated with the use of TI for toxicity analysis. We show 
that it contains more information than other toxicity analysis methods by accounting for both the 
multiplicity and severity of toxicities, without losing the natural interpretability of the maximum 
grade approach. This added information provides greater power to examine comparisons across 
treatment types when compared to the maximum grade and average toxicity approaches, 
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resulting in the least number of patients required to detect differences between treatments, and 
consequently saving trial resources and time.  
As a limitation, the use of TI requires rank-based methods because it does not follow any 
well-known probability distribution such as the normal distribution. These methods are less 
powerful than parametric approaches, and rank-based regressions such as PIM are less 
disseminated. Although one could argue that the decreased power is mitigated due the large 
sample sizes used in phase III clinical trials, the lack of a distribution assumption makes our 
conclusions more robust. Furthermore, the TI can be applied to other ordinal scales such as the 
PRO-CTCAE, which is increasingly being introduced into clinical trial data collection and 
analysis.31,32  The use of patient-reported toxicities also addresses deficiencies of clinician-rated 
CTCAE toxicities that lack standardization, are not systematically rated, are difficult to assess 
due to their subjective nature (e.g. pain, fatigue, anxiety), leading to underreporting of the 
frequency and severity of symptoms. Detailed analysis of PRO data from the quality of life 
questionnaire from the NSABP R04 trial will be presented in an independent report. Future 
applications of TI may also incorporate weights for different toxicities as determined a priori by 
investigators or patients and included in the analysis of toxicities in clinical trials. 
A limitation of this study was the availability of only a single AE assessment time point 
in the NSABP R04 clinical trial. We plan to explore the use of TI for longitudinal evaluations 
and compare to other methods that require repeated measures such as Tox-T15 and TAME33 to 
assess whether the benefits of the TI approach hold. While this was previously challenging using 
rank-based approaches, there are recently-developed methods that can allow for this analysis and 
be applied to the comparison of treatments using TI.34,35     
In conclusion, this research used standard data collected in a cancer clinical trial to 
introduce descriptive and analytic methods that account for the additional burden of multiple 
toxicities. Our findings demonstrate initial feasibility of TI and its added value in the analysis of 
toxicity data to improve our understanding of the comparative tolerability across different 
treatments. These methods may provide a more accurate account of treatment tolerability that 
could lead to individualized dosing for better toxicity control. Future research will validate the 
clinical findings observed in the R04 trials with additional trials that used similar drugs. 
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Figure Titles and Legends 
Figure 1. CONSORT Diagram.  
5FU: 5-fluorouracil; CAPE: Capecitabine; Oxa: Oxaliplatin 
 
*Main study description available in Allegra et al. (2015). All treatment arms included radiation therapy. 
†Pre-amendment: In 2004, patients were randomly assigned to either RT+5FU or RT+CAPE for 7 days a week 
beginning the day of RT start and ending on the last dose of RT.  
‡Post-amendment: In 2005, the  protocol was amended to add Oxa and resulted in a 2x2 factorial design. Doses were 
reduced from 7 days to 5 days. 
 
Figure 2. Relative percentages of toxicities per patient by treatment arm 
5FU: 5-fluorouracil; CAPE: Capecitabine; Oxa: Oxaliplatin 
The x-axis represents the number of adverse events observed per patient. The y-axis represents the percentage of the 
total associated with each number of adverse events within each treatment arm. Each column is further broken down 
and color coded by grade, from no adverse events (Grade 0) represented as green to most severe (Grade 5) 
represented as red. The labeling within each column represents the relative percentage of a given grade among 
patients with the specified number of adverse events (grades with less than 1 percent are omitted). The table inset 
presents the grade (G), count (C), and percent (%) of each grade observed for a given treatment arm. 
 
Figure 3. Relationship between Toxicity Index and Number of Toxicities per Patient by 
Treatment Arm 
5FU: 5-fluorouracil; CAPE: Capecitabine; Oxa: Oxaliplatin 
 
Figure 4. Multivariable Probabilistic Index Model Results by Treatment Comparison and 
Analytic Method. 
5FU: 5-fluorouracil; CAPE: Capecitabine; Oxa: Oxaliplatin 
Each bar represents the probability index and 95% confidence intervals. 
 
Figure 5. Power to Detect Treatment Differences for Toxicity Index, Maximum Grade, and 
Mean Toxicity Methods 
5FU: 5-fluorouracil; CAPE: Capecitabine; Oxa: Oxaliplatin 
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Tables 
Table 1. Measures of Central Tendency of the Toxicity Index by Treatment   
 
Treatment* 
Number of 
Patients 
Number of toxicities Mean (SD) Median [IQR] 
5FU (2 Arm) 141 385 3.56 (2.81) 3 [1, 5] 
5FU (4 Arm) 316 706 3.28 (2.85) 2 [1, 4] 
5FU + Oxa (4 Arm) 321 1121 4.36 (3.65) 3 [2, 6] 
CAPE (2 Arm) 141 455 4.21 (3.83) 3 [2, 5] 
CAPE (4 Arm) 318 761 3.43 (2.59) 3 [1, 5] 
CAPE + Oxa (4 Arm) 321 1132 4.51 (3.73) 3 [2, 6] 
*5FU: 5-fluorouracil; CAPE: Capecitabine; Oxa: Oxaliplatin 
SD = standard deviation, IQR = Interquartile range. 
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Table 2. Multivariable Probabilistic Index* for Toxicity Index Comparing 4-Arm and 2-Arm trials  
Variable Comparison* 5-FLUOROURACIL CAPECITABINE 
A < B Probability (95% CI) P-Value§ Probability (95% CI) P-Value§ 
Treatment 4 Arm† < 2 Arm 0.570 (0.513 – 0.625) 0.02 0.558 (0.499 – 0.615) 0.054 
Gender Male < Female 0.571 (0.513 – 0.628) 0.02 0.609 (0.551 – 0.664) <0.001 
Age (Years) (Every five years) 0.511 (0.499 – 0.522) 0.07 0.508 (0.496 – 0.520) 0.18 
Karnofsky PS 
 
90-100 < 70-80 0.605 (0.532 – 0.673) 0.005 0.579 (0.503 – 0.653) 0.043 
90-100 < 50-60 N/A N/A 0.933 (0.916 – 0.947) <0.001 
Clinical stage 
N 
Negative < Positive 0.492 (0.438 – 0.547) 0.78 0.522 (0.468 – 0.576) 0.41 
Sphincter-
saving surgery 
Yes < No 0.503 (0.445 – 0.562) 0.92 0.508 (0.448 – 0.568)  0.79 
Clinical stage 
T 
 T1/T2/T3 < T4 0.537 (0.383 – 0.684)  0.64 0.505 (0.384 – 0.626)  0.93 
BMI (kg/m2) LT‡ 18.5 < 18.5 - 25 0.467 (0.241 – 0.708) 0.80 0.369 (0.226 – 0.541) 0.13 
LT 18.5 < 25-30 0.445 (0.224 – 0.690) 0.67 0.362 (0.221 – 0.532) 0.11 
LT 18.5 < GE 30 0.417 (0.206 – 0.664) 0.52 0.309 (0.183 – 0.471) 0.02 
*Probabilistic Model Interpretation: Comparison A<B denotes the probability that toxicity index for B is higher than 
toxicity index for A. Probability of 0.5 indicates no difference between comparisons (A=B). If Probability > 0.5, 
then probability of toxicity index for B is greater than A is high indicating that B has higher toxicity. If the 
probability < 0.5, then probability of toxicity index for B greater than A is small indicating that A has higher 
toxicity. Multivariable models were adjusted for gender, 4-arm treatments, age, BMI, clinical T stage, clinical N 
stage, sphincter-saving surgery, and Karnofsky performance status (PS). 
†The trial was amended in 2005 to add Oxaliplatin to each of the arms. The doses for 5FU and CAPE for the 4-arm 
clinical trial were reduced from seven days (2-Arm trial) to five days (4-Arm trials) a week at the same daily dose.  
‡LT=Less Than; GE= Greater or equal to 
§All P-values are two-sided and were calculated using the Wald statistic. P-values for multiple comparisons were 
corrected using Holm’s adjustment.  
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Table 3. Multivariable Probabilistic Index* for Toxicity Index Comparing 4-Arm and 2-Arm trials†  
Variable 
  
Comparison 
A < B 
Probability (95% CI) P-value§ 
Treatment 
 
5FU < 5FU + Oxa 0.619 (0.560 – 0.674) <0.001 
5FU < CAPE 0.533 (0.472 – 0.593) 0.30 
5FU < CAPE + Oxa 0.627 (0.568 – 0.682) <0.001 
CAPE < 5FU + Oxa 0.587 (0.527 – 0.644) <0.001 
CAPE < CAPE + Oxa 0.596 (0.536 – 0.653) <0.001 
5FU + Oxa < CAPE + Oxa 0.509 (0.449 – 0.569 0.70 
Gender Male < Female 0.623 (0.589 – 0.655) <0.001 
Age, Years (Every five years) 0.507 (0.500 – 0.515) 0.04 
Karnofsky PS 90-100 < 70-80 0.575 (0.529 – 0.619) 0.001 
Clinical stage N Negative < Positive 0.480 (0.447 – 0.513) 0.24 
Sphincter- Saving Surgery Yes < No 0.540 (0.504 – 0.577) 0.03 
Clinical stage T T1-3 < T4 0.551 (0.468 – 0.632) 0.23 
BMI (kg/m2) 
 
LT‡ 18.5 < 18.5 - 25 0.441 (0.311 – 0.580) 0.49 
LT 18.5 < 25-30 0.403 (0.278 – 0.542) 0.17 
LT 18.5 < GE 30 0.360 (0.243 – 0.495) 0.04 
*Probabilistic Model Interpretation: Comparison A<B denotes the probability that toxicity index for B is higher than 
toxicity index for A. Probability of 0.5 indicates no difference between comparisons (A=B). If Probability > 0.5, 
then probability of toxicity index for B is greater than A is high indicating that B has higher toxicity. If the 
probability < 0.5, then probability of toxicity index for B greater than A is small indicating that A has higher 
toxicity. Multivariable models were adjusted for gender, 4-arm treatments, age, BMI, clinical T stage, clinical N 
stage, sphincter-saving surgery, and Karnofsky performance status (PS). 
†The trial was amended in 2005 to add Oxaliplatin (Oxa) to each of the arms. The doses for 5-fluorouracil (5FU) and 
Capecitabine (CAPE) for the 4-arm clinical trial were reduced from seven days (2-Arm trial) to five days (4-Arm 
trials) a week at the same daily dose.  
‡LT=Less Than; GE= Greater or equal to 
§All P-values are two-sided and were calculated using the Wald statistic. P-values for multiple comparisons were 
corrected using Holm’s adjustment.  
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Table 4. Multivariable Probabilistic Index Models* for System Organ Class-specific Toxicity Index 
Comparing Gender  
 
System Organ 
Class (SOC) 
Number of 
observations 
with non-zero 
SOC-specific 
Toxicity Index† 
Probability‡ 
(95% CI§) 
P-Value¶ 
Blood 136 0.553 (0.522 – 0.584) <.001 
Cardiac 14 Not examined due to a small number of nonzero values 
Ear 2 Not examined due to a small number of nonzero values 
Endocrine 1 Not examined due to a small number of nonzero values 
Eye 8 Not examined due to a small number of nonzero values 
Gastrointestinal 672 0.616 (0.566 – 0.662) <.001 
General 362 0.563 (0.521 – 0.604) <.001 
Hepatobiliary 3 Not examined due to a small number of nonzero values 
Immune 26 0.501 (0.489 – 0.514) 1.00 
Infections 91 0.518 (0.494 – 0.543) 0.26 
Injury 198 0.511 (0.479 – 0.544) 1.00 
Investigations 299 0.572 (0.532 – 0.612) <.001 
Metabolism 251 0.554 (0.517 – 0.591) <.001 
Musculoskeletal 71 0.507 (0.486 – 0.528) 1.00 
Nervous 116 0.506 (0.480 – 0.533) 1.00 
Psychiatric 62 0.500 (0.480 – 0.519) 1.00 
Renal 130 0.500 (0.472 – 0.527) 1.00 
Reproductive 22 0.522 (0.506 – 0.538) 0.001 
Respiratory 29 0.501 (0.488 – 0.515) 1.00 
Skin 114 0.512 (0.486 – 0.538) 1.00 
Vascular 70 0.519 (0.497 – 0.540) 0.10 
*Multivariable models were adjusted for gender, 4-arm treatments, age, BMI, clinical T stage, clinical N stage, 
sphincter-saving surgery, and Karnofsky performance status. 
†From a total of 1,276 observations. 
‡Probability that SOC-specific toxicity index for females is higher than SOC-specific toxicity index for males. 
§Adjusted for multiple tests using the Bonferroni procedure. 
¶ All P-values are two-sided and were calculated using the Wald statistic. P-values for multiple comparisons were 
corrected using Holm’s adjustment. 
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